Insulet Corporation (PODD)

Nov 7, 2026

DexCom (DXCM) stock fell 6.0% on Friday, November 6, 2026, without company-specific news, echoing similar declines in peers Insulet and Tandem Diabetes Care. Tandem's earnings call revealed slower-than-expected pharmacy distribution which could impact 2027 revenue growth, potentially affecting DexCom due to its presence in the same diabetes market. Despite this recent fall, DexCom's shares have returned 34.0% over the past year, significantly outperforming the S&P 500.

Nov 3, 2026

This article analyzes Insulet Corporation (NASDAQ: PODD) using AI models, identifying strong near and mid-term sentiment but a weak long-term outlook. It presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also highlights support and resistance levels across different time horizons for informed decision-making.

Oct 29, 2026

Insulet Corp. (PODD) stock rose 2.40% to $152.50 on Thursday, despite a broader market downturn where the S&P 500 Index and Dow Jones Industrial Average both fell. The company's stock closed 57.03% below its 52-week high of $354.88 achieved on November 20th. This performance indicates that Insulet Corp. underperformed relative to its competitors even with daily gains.

Oct 27, 2026

Beta Bionics reported Q3 2026 net sales of $35.5 million, a 30% year-over-year growth, and received FDA clearance for Mint, a new patch pump set to launch in Q1 2027. The company raised $161 million to support Mint's commercialization and updated its full-year 2026 revenue guidance to $124-$126 million. They are also progressing with new algorithm developments and a pivotal trial for a fully closed-loop system, despite a temporary withdrawal and resubmission of their 3D Intelligence algorithm to the FDA.

Oct 27, 2026

vTv Therapeutics Inc. has announced the randomization of the first participant in its Phase 2a Hybrid CATT1 pilot study. This study will evaluate cadisegliatin, an investigational oral therapy, in individuals with Type 1 Diabetes (T1D) who use hybrid closed-loop (HCL) insulin delivery systems. The company aims for the results to provide insights into cadisegliatin's potential in this T1D population segment and to inform future clinical studies.